Welcome to the Colorado State University
Research Innovation Center
Current Tenant Companies
E-Flux strives to solve environmental problems with unique and simple solutions. Products include Fossil Fuel Traps, which were conceived as a cost-effective solution to the complex problem of accurately measuring petroleum biodegredation rates in soil at petroleum spill sites. The second product offering, Map Traps, utilize similar but less sensitive testing capabilities. Map Traps are used to delineate petroleum based contaminated areas by providing a binary (yes / no) indication of the presence of petroleum. A third product, BioTherm, is a web-based thermal modeling tool used to enhance the conceptual site model.
GT Molecular was created to develop new molecular detection technology for cancer research and harmful pathogen detection. We have recently focused these powerful tools on the detection of SARS-CoV-2 in wastewater to support communities around the country with their monitoring programs. Ultrasensitive Molecular Assays, Digital PCR and qPCR Tests, End-to-End solutions for cancer detection and waterborne pathogens including SARS-CoV-2. Detect as little as 1-3 molecules of target DNA.
PhotonPharma is developing its InnocellTM antigen presenting technology for personalized same-day immunotherapy for solid or liquid tumors.
SiVEC Biotechnologies is committed to developing antiviral products for the rapid prevention of economically important diseases. SiVEC’s patent pending antiviral technology, SiVEC-AIV™, can be rapidly applied as a large-scale aerosol to prevent avian flu in poultry, thereby significantly reducing the economic impact of this disease worldwide.
Vivaldi Biosciences is a clinical-stage biotechnology company developing live attenuated influenza vaccines (LAIVs) to address the most pressing public health issues of influenza: the need for a rapid and effective response to emerging pandemics with vaccines that are easily administered, safe and protective, and the need for vaccines that protect the most vulnerable populations – seniors and young children – against seasonal influenza. These age groups suffer disproportionately from influenza and its serious complications, but are poorly served by conventional influenza vaccines.
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2018, the company generated annual revenue of $5.8 billion with approximately 10,000 employees. For more information, visit https://www.zoetisus.com/